Valuation: Danaher Corporation

Market Cap 150B 134B 125B 114B 215B 14,466B 217B 1,510B 585B 7,395B 565B 553B 23,734B P/E 2026 *
36.3x
P/E 2027 * 29.6x
Enterprise Value 171B 152B 142B 129B 244B 16,446B 246B 1,717B 665B 8,408B 642B 628B 26,983B EV / Sales 2026 *
6.5x
EV / Sales 2027 * 5.86x
Free-Float
70.45%
Yield 2026 *
0.66%
Yield 2027 * 0.73%
1 day-1.17%
Current month-4.06%
Current year-4.06%
1 year 179.36
Extreme 179.36
186.95
3 years 179.36
Extreme 179.36
186.95
5 years 179.36
Extreme 179.36
186.95
10 years 75.1
Extreme 75.1
186.95
Manager TitleAgeSince
Chief Executive Officer 62 01/09/2020
Director of Finance/CFO - 28/02/2026
Chief Tech/Sci/R&D Officer - 25/08/2025
Director TitleAgeSince
Director/Board Member 74 01/07/1999
Chairman 74 01/01/1984
Director/Board Member 69 01/01/1984
Change 5-day change 1-year change 3-year change Capi.($)
-1.17%-2.93% - - 150B
+0.35%-2.99%+20.52%+31.06% 242B
+1.09%-4.65%-0.43%-0.76% 150B
-2.32%-3.27%-13.35%+36.07% 138B
-1.46%-3.01%-56.23%-17.35% 61.74B
-0.05%-1.32%+10.48%+22.34% 49.08B
+0.66%+0.19%-20.53%-20.70% 47.43B
+0.66%-2.90%+18.46%+52.17% 47.3B
-3.05%-2.62%-7.75%+36.49% 44.25B
-0.08%-1.92%+29.48%+60.45% 41.78B
Average -0.54%-2.50%-2.15%+22.20% 91.4B
Weighted average by Cap. -0.43%-3.27%+1.08%+21.95%

Financials

2026 *2027 *
Net sales 26.34B 23.4B 21.84B 19.91B 37.55B 2,532B 37.9B 264B 102B 1,294B 98.89B 96.74B 4,154B 28.46B 25.29B 23.6B 21.51B 40.57B 2,736B 40.95B 286B 111B 1,399B 107B 105B 4,489B
Net income 4.18B 3.71B 3.47B 3.16B 5.96B 402B 6.01B 41.95B 16.26B 205B 15.7B 15.36B 659B 5.14B 4.57B 4.26B 3.88B 7.33B 494B 7.39B 51.58B 19.99B 253B 19.3B 18.88B 811B
Net Debt 20.6B 18.3B 17.08B 15.57B 29.37B 1,980B 29.64B 207B 80.11B 1,012B 77.34B 75.66B 3,249B 16.19B 14.38B 13.43B 12.24B 23.08B 1,556B 23.29B 162B 62.96B 796B 60.78B 59.46B 2,553B
Logo Danaher Corporation
Danaher Corporation is an industrial and technologic group organized around three families of products: - diagnostic equipment (40.5% of net sales); - life sciences equipment (29.8%); - biotechnology equipment (29.7%): ranging from basic biological research to the development and manufacturing of vaccines, biological drugs, cell and gene therapies, and new technologies such as mRNA. Net sales are distributed geographically as follows: the United States (40.6%), China (10.7%) and other (48.7%).
Employees
59,000
Date Price Change
02/10/26 CHF 179.36 -1.17%
01/10/26 CHF 181.48 -2.90%
28/09/26 CHF 186.90 +1.15%
25/09/26 CHF 184.78 +0.75%
24/09/26 CHF 183.40 +1.06%
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
214.06USD
Average target price
234.73USD
Spread / Average Target
+9.65%

Quarterly revenue - Rate of surprise